Schroder Investment Management Group Has $58.74 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Schroder Investment Management Group trimmed its position in Natera, Inc. (NASDAQ:NTRA) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 370,460 shares of the medical research company’s stock after selling 63,059 shares during the quarter. Schroder Investment Management Group owned about 0.28% of Natera worth $58,736,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Natera during the 3rd quarter worth about $385,000. Everence Capital Management Inc. bought a new stake in shares of Natera in the fourth quarter valued at approximately $573,000. Smartleaf Asset Management LLC grew its stake in shares of Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock worth $104,000 after acquiring an additional 220 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Natera by 87.3% in the third quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock worth $8,621,000 after acquiring an additional 31,649 shares during the last quarter. Finally, SeaBridge Investment Advisors LLC bought a new position in Natera during the fourth quarter worth $2,894,000. 99.90% of the stock is owned by institutional investors.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 25,931 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the transaction, the chief financial officer now owns 109,665 shares in the company, valued at approximately $18,091,435.05. The trade was a 19.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 306,797 shares of company stock worth $48,940,883 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NTRA shares. Morgan Stanley lifted their target price on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. BTIG Research restated a “buy” rating on shares of Natera in a research note on Friday, February 28th. Barclays assumed coverage on shares of Natera in a research note on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Stock Performance

Natera stock opened at $141.41 on Tuesday. The business has a 50 day moving average of $159.26 and a 200-day moving average of $151.25. The company has a market capitalization of $19.12 billion, a P/E ratio of -80.35 and a beta of 1.80. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.